(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Baxalta Inc's Vonvendi, making it the first engineered protein-based treatment for the world's most common inherited bleeding disorder.
http://ift.tt/xePdMM
from Reuters: Health News
via
animenewspro
Aucun commentaire:
Enregistrer un commentaire